Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has reiterated a Neutral rating on CRISPR Therapeutics (NASDAQ:CRSP), indicating no change in the firm's stance towards the company's stock.
May 09, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Eric Schmidt reiterated a Neutral rating on CRISPR Therapeutics, suggesting no immediate bullish or bearish outlook for the stock.
The reiteration of a Neutral rating by a significant analyst suggests that there are no immediate catalysts expected to significantly move the stock price in either direction. This rating indicates a hold position, implying that the analyst sees the stock as fairly valued at its current price, with no strong short-term growth or decline indicators.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100